The GlaxoSmithKline (GSK) pharmaceutical laboratory may have found the right one with a vaccine that is set to immediately enter phase III clinical trials. It has already succesfully tested on American volunteers and on 340 Tanzanian children. It seems to reduce the infection risk by 65% – without unpleasant interaction.
All people traveling to tropical countries will certainly be glad to hear this, for themselves and for the people of these countries paying a dire price to the malaria infection.
Other similar articles:
feed of the comments.